+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Oncology Biosimilars Market - Global Forecast 2025-2030- Product Image
Oncology Biosimilars Market - Global Forecast 2025-2030- Product Image
Sale

Oncology Biosimilars Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 186 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 4968765
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The oncology biosimilars market is evolving rapidly, presenting senior leaders with new efficiency and value levers for oncology drug development and commercialization. With industry forces transforming patient access, pricing approaches, and global distribution, decision-makers face an environment where strategic clarity and agility are essential.

Market Snapshot: Oncology Biosimilars Market Size and Growth

The Oncology Biosimilars Market grew from USD 5.48 billion in 2024 to USD 6.51 billion in 2025. It is expected to continue growing at a CAGR of 18.16%, reaching USD 14.94 billion by 2030. This sustained expansion is underpinned by adoption across key geographies, diversified product pipelines, and the ongoing integration of biosimilars into mainstream cancer care. The landscape reflects a maturing industry with broadening payer acceptance and evolving commercial frameworks.

Scope & Segmentation of the Oncology Biosimilars Market

  • Product Type: Bevacizumab, Cetuximab, Rituximab, Trastuzumab.
  • Therapeutic Indication: Breast Cancer, Colorectal Cancer, Gastric Cancer, Lung Cancer, Non-Hodgkin's Lymphoma.
  • Route of Administration: Intravenous Infusion, Subcutaneous Injection.
  • Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Specialty Pharmacies.
  • Regional Coverage: Americas (United States - California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada; Mexico; Brazil; Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Leading Companies: Pfizer Inc., Sandoz AG, Celltrion, Inc., Amgen Inc., Samsung Bioepis Co., Ltd., Biocon Limited, Viatris Inc., Fresenius Kabi AG, Dr. Reddy's Laboratories Limited, Teva Pharmaceutical Industries Ltd.

Key Takeaways for Oncology Biosimilars Decision-Makers

  • Industry innovation is accelerating through advanced R&D methodologies, including AI-driven validation, cell line engineering, and digital manufacturing technology.
  • Commercial models are shifting toward value-based contracts and early stakeholder engagement, aligning clinical development with outcomes and payer needs.
  • Regulatory harmonization and improvements in interchangeability guidelines are streamlining biosimilar approvals, fostering trust and aiding global adoption.
  • Strategic partnerships are expanding, with manufacturers forming alliances along the supply and value chain to ensure scalability and enhance distribution.
  • Channel strategies are being tailored, with organizations optimizing patient support and cold chain distribution for both hospital and non-hospital channels.
  • Segmentation by therapy, administration, and indication enables targeted investment and clinical planning for diverse oncology needs.

Tariff Impact on Oncology Biosimilar Supply Chains and Pricing

The 2025 United States tariffs on imported biologics and raw materials have driven operational shifts across the biosimilar market. Manufacturers have responded by reassessing sourcing, investing in regional and nearshore production, and adopting supply chain analytics such as digital twin simulations. Pricing models are being recalibrated—some firms absorb costs to remain competitive, while others renegotiate contracts or integrate vertically for greater control. These measures optimize both resilience and market agility, prompting redefined procurement and commercial strategies in oncology biosimilars.

Oncology Biosimilars Market Methodology & Data Sources

This research integrates in-depth primary interviews with stakeholders—oncologists, regulators, payers, and manufacturing leaders—alongside a comprehensive review of published clinical results, regulatory filings, and financial disclosures. Proprietary reports and scenario-based quantitative models provide grounded insights into product launches, regulatory trends, and supply chain impacts. Triangulation and digital analytics ensure the validity and reliability of findings throughout the oncology biosimilars market study.

Why This Report Matters for Oncology Biosimilars Stakeholders

  • Enables timely, informed decision-making on product development, commercialization, and risk mitigation amid evolving oncology biosimilar dynamics.
  • Equips executive teams with product, regional, and operational intelligence needed to prioritize growth opportunities and enhance portfolio strategies.
  • Offers actionable recommendations tailored to supply chain complexity, regulatory change, and stakeholder engagement across both mature and emerging regions.

Conclusion

Oncology biosimilars are reshaping global cancer care. Strategic foresight and data-driven approaches will be essential for capturing value as market competition intensifies and new pathways to growth emerge.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Comparative clinical efficacy and immunogenicity evaluation of adalimumab oncology biosimilars in real world settings
5.2. Impact of oncology biosimilar uptake on healthcare budgets and payer reimbursement strategies in major markets
5.3. Regulatory pathway harmonization efforts for fast-tracking oncology biosimilars across the US and EU
5.4. Strategic collaborations between biopharma incumbents and biosimilar developers to optimize oncology market penetration
5.5. Emerging patent litigation and exclusivity challenges delaying launch of trastuzumab biosimilars in global markets
5.6. Advancements in manufacturing scalability and process optimization reducing costs for high volume oncology biosimilars
5.7. Strategies to build physician and patient trust in oncology biosimilars through targeted educational initiatives
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Oncology Biosimilars Market, by Product Type
8.1. Introduction
8.2. Bevacizumab
8.3. Cetuximab
8.4. Rituximab
8.5. Trastuzumab
9. Oncology Biosimilars Market, by Therapeutic Indication
9.1. Introduction
9.2. Breast Cancer
9.3. Colorectal Cancer
9.4. Gastric Cancer
9.5. Lung Cancer
9.6. Non-Hodgkin's Lymphoma
10. Oncology Biosimilars Market, by Route Of Administration
10.1. Introduction
10.2. Intravenous Infusion
10.3. Subcutaneous Injection
11. Oncology Biosimilars Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
11.5. Specialty Pharmacies
12. Americas Oncology Biosimilars Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Oncology Biosimilars Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Oncology Biosimilars Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Pfizer Inc.
15.3.2. Sandoz AG
15.3.3. Celltrion, Inc.
15.3.4. Amgen Inc.
15.3.5. Samsung Bioepis Co., Ltd.
15.3.6. Biocon Limited
15.3.7. Viatris Inc.
15.3.8. Fresenius Kabi AG
15.3.9. Dr. Reddy's Laboratories Limited
15.3.10. Teva Pharmaceutical Industries Ltd.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. ONCOLOGY BIOSIMILARS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ONCOLOGY BIOSIMILARS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. ONCOLOGY BIOSIMILARS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. ONCOLOGY BIOSIMILARS MARKET: RESEARCHAI
FIGURE 24. ONCOLOGY BIOSIMILARS MARKET: RESEARCHSTATISTICS
FIGURE 25. ONCOLOGY BIOSIMILARS MARKET: RESEARCHCONTACTS
FIGURE 26. ONCOLOGY BIOSIMILARS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ONCOLOGY BIOSIMILARS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY CETUXIMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY CETUXIMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY RITUXIMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY TRASTUZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY TRASTUZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY GASTRIC CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY GASTRIC CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY NON-HODGKIN'S LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY NON-HODGKIN'S LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 48. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 49. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 50. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 51. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 52. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 53. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 54. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 55. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 56. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 57. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 58. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 59. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 60. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 61. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 62. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 63. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 64. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 65. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 66. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 67. CANADA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 68. CANADA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 69. CANADA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 70. CANADA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 71. CANADA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 72. CANADA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 73. CANADA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 74. CANADA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 75. MEXICO ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 76. MEXICO ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 77. MEXICO ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 78. MEXICO ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 79. MEXICO ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 80. MEXICO ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 81. MEXICO ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 82. MEXICO ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 83. BRAZIL ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 84. BRAZIL ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 85. BRAZIL ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 86. BRAZIL ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 87. BRAZIL ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 88. BRAZIL ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 89. BRAZIL ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 90. BRAZIL ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 91. ARGENTINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 92. ARGENTINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 93. ARGENTINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 94. ARGENTINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 95. ARGENTINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 96. ARGENTINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 97. ARGENTINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 98. ARGENTINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 110. UNITED KINGDOM ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 112. UNITED KINGDOM ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 113. UNITED KINGDOM ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 114. UNITED KINGDOM ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 115. UNITED KINGDOM ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 116. UNITED KINGDOM ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 117. GERMANY ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 118. GERMANY ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 119. GERMANY ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 120. GERMANY ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 121. GERMANY ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 122. GERMANY ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 123. GERMANY ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 124. GERMANY ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 125. FRANCE ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 126. FRANCE ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 127. FRANCE ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 128. FRANCE ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 129. FRANCE ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 130. FRANCE ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 131. FRANCE ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 132. FRANCE ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 133. RUSSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 134. RUSSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 135. RUSSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 136. RUSSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 137. RUSSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 138. RUSSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 139. RUSSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 140. RUSSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 141. ITALY ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 142. ITALY ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 143. ITALY ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 144. ITALY ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 145. ITALY ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 146. ITALY ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 147. ITALY ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. ITALY ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. SPAIN ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 150. SPAIN ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 151. SPAIN ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 152. SPAIN ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 153. SPAIN ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 154. SPAIN ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 155. SPAIN ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 156. SPAIN ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 157. UNITED ARAB EMIRATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 158. UNITED ARAB EMIRATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 159. UNITED ARAB EMIRATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 160. UNITED ARAB EMIRATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 161. UNITED ARAB EMIRATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 162. UNITED ARAB EMIRATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 163. UNITED ARAB EMIRATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 164. UNITED ARAB EMIRATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 165. SAUDI ARABIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 166. SAUDI ARABIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 167. SAUDI ARABIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 168. SAUDI ARABIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 169. SAUDI ARABIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 170. SAUDI ARABIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 171. SAUDI ARABIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 172. SAUDI ARABIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 173. SOUTH AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 174. SOUTH AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 175. SOUTH AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 176. SOUTH AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 177. SOUTH AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 178. SOUTH AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 179. SOUTH AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 180. SOUTH AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 181. DENMARK ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 182. DENMARK ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 183. DENMARK ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 184. DENMARK ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 185. DENMARK ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 186. DENMARK ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 187. DENMARK ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 188. DENMARK ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 189. NETHERLANDS ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 190. NETHERLANDS ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 191. NETHERLANDS ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 192. NETHERLANDS ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 193. NETHERLANDS ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 194. NETHERLANDS ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 195. NETHERLANDS ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 196. NETHERLANDS ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 197. QATAR ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 198. QATAR ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 199. QATAR ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 200. QATAR ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 201. QATAR ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 202. QATAR ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 203. QATAR ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 204. QATAR ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 205. FINLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 206. FINLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 207. FINLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 208. FINLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 209. FINLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 210. FINLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 211. FINLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 212. FINLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 213. SWEDEN ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 214. SWEDEN ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 215. SWEDEN ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 216. SWEDEN ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 217. SWEDEN ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 218. SWEDEN ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 219. SWEDEN ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 220. SWEDEN ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 221. NIGERIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 222. NIGERIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 223. NIGERIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 224. NIGERIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 225. NIGERIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 226. NIGERIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 227. NIGERIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 228. NIGERIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 229. EGYPT ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 230. EGYPT ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 231. EGYPT ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 232. EGYPT ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 233. EGYPT ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 234. EGYPT ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 235. EGYPT ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 236. EGYPT ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 237. TURKEY ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 238. TURKEY ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 239. TURKEY ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 240. TURKEY ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 241. TURKEY ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 242. TURKEY ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 243. TURKEY ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 244. TURKEY ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 245. ISRAEL ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 246. ISRAEL ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 247. ISRAEL ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 248. ISRAEL ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 249. ISRAEL ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 250. ISRAEL ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 251. ISRAEL ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 252. ISRAEL ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 253. NORWAY ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 254. NORWAY ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 255. NORWAY ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 256. NORWAY ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 257. NORWAY ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 258. NORWAY ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 259. NORWAY ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 260. NORWAY ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 261. POLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 262. POLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 263. POLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 264. POLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 265. POLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 266. POLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 267. POLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 268. POLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 269. SWITZERLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 270. SWITZERLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 271. SWITZERLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 272. SWITZERLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 273. SWITZERLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 274. SWITZERLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 275. SWITZERLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 276. SWITZERLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 277. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 278. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 279. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 280. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 281. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 282. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 283. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 284. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 285. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 286. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 287. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 288. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 289. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 290. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 291. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 292. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 293. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 294. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 295. INDIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 296. INDIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 297. INDIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 298. INDIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 299. INDIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 300. INDIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 301. INDIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 302. INDIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 303. JAPAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 304. JAPAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 305. JAPAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 306. JAPAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 307. JAPAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 308. JAPAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 309. JAPAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 310. JAPAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 311. AUSTRALIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 312. AUSTRALIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 313. AUSTRALIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 314. AUSTRALIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 315. AUSTRALIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 316. AUSTRALIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 317. AUSTRALIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 318. AUSTRALIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 319. SOUTH KOREA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 320. SOUTH KOREA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 321. SOUTH KOREA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 322

Samples

Loading
LOADING...

Companies Mentioned

  • Pfizer Inc.
  • Sandoz AG
  • Celltrion, Inc.
  • Amgen Inc.
  • Samsung Bioepis Co., Ltd.
  • Biocon Limited
  • Viatris Inc.
  • Fresenius Kabi AG
  • Dr. Reddy's Laboratories Limited
  • Teva Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages186
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 6.51 Billion
Forecasted Market Value ( USD ) by 2030 $ 14.94 Billion
Compound Annual Growth Rate18.1%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Trastuzumab Biosimilars Market - Global Forecast 2025-2030 - Product Image

Trastuzumab Biosimilars Market - Global Forecast 2025-2030

  • Report
  • 182 Pages
  • Global
From
Biosimilar Monoclonal Antibodies Market - Global Forecast 2025-2030 - Product Image

Biosimilar Monoclonal Antibodies Market - Global Forecast 2025-2030

  • Report
  • 198 Pages
  • Global
From
Oncology Biosimilars Market Report by Drug Type, and Region 2025-2033 - Product Image

Oncology Biosimilars Market Report by Drug Type, and Region 2025-2033

  • Report
  • 140 Pages
  • Global
From
Biosimilar Market Report 2025-2033 - Product Image

Biosimilar Market Report 2025-2033

  • Report
  • 123 Pages
  • Global
From
Biosimilars - Global Strategic Business Report - Product Image

Biosimilars - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From

About the Oncology Biosimilars Market

Oncology Biosimilars are biotechnology-based drugs that are designed to replicate the therapeutic effects of existing biologic drugs used to treat cancer. These drugs are developed using advanced biotechnology techniques, such as recombinant DNA technology, to create a molecule that is similar to the original biologic drug. Oncology Biosimilars are intended to provide a cost-effective alternative to the original biologic drug, while still providing the same therapeutic benefits. Oncology Biosimilars are regulated by the FDA and must meet the same safety and efficacy standards as the original biologic drug. The approval process for Oncology Biosimilars is more rigorous than that of generic drugs, as the FDA requires additional clinical trials to demonstrate the safety and efficacy of the drug. Oncology Biosimilars are becoming increasingly popular as a cost-effective alternative to the original biologic drugs. As the cost of biologic drugs continues to rise, Oncology Biosimilars offer a more affordable option for patients. Some companies in the Oncology Biosimilars market include Amgen, Pfizer, Merck, and Novartis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.